On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there...Show More

On February 2, 2024, Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, reported a significant stake in Invivyd, Inc. According to the Schedule 13G filed with the SEC, the group collectively owns 9,000,000 shares of Invivyd's common stock, which represents 7.56% of the company's class of securities. The filing, made under Rule 13d-1(c), indicates that the shares are held with shared voting and dispositive power. The principal business offices for Deep Track Capital and David Kroin are located in Greenwich, CT, while Deep Track Biotechnology Master Fund is based in the Cayman Islands. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Invivyd, Inc., and there is no intention to participate in any transaction with such a purpose or effect. The statement was duly signed by David Kroin, who serves as the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and as a Director for Deep Track Biotechnology Master Fund, Ltd.